In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census
Open Access
- 4 November 2012
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 1 (8) , 1281-1289
Abstract
Antigen-specific immune responses against peptides derived from missense gene mutations have been identified in multiple cancers. The application of personalized peptide vaccines based on the tumor mutation repertoire of each cancer patient is a near-term clinical reality. These peptides can be identified for pre-validation by leveraging the results of massive gene sequencing efforts in cancer. In this study, we utilized NetMHC 3.2 to predict nanomolar peptide binding affinity to 57 human HLA-A and B alleles. All peptides were derived from 5,685 missense mutations in 312 genes annotated as functionally relevant in the Cancer Genome Project. Of the 26,672,189 potential 8–11 mer peptide-HLA pairs evaluated, 0.4% (127,800) display binding affinities < 50 nM, predicting high affinity interactions. These peptides can be segregated into two groups based on the binding affinity to HLA proteins relative to germline-encoded sequences: peptides for which both the mutant and wild-type forms are high affinity binders, and peptides for which only the mutant form is a high affinity binder. Current evidence directs the attention to mutations that increase HLA binding affinity, as compared with cognate wild-type peptide sequences, as these potentially are more relevant for vaccine development from a clinical perspective. Our analysis generated a database including all predicted HLA binding peptides and the corresponding change in binding affinity as a result of point mutations. Our study constitutes a broad foundation for the development of personalized peptide vaccines that hone-in on functionally relevant targets in multiple cancers in individuals with diverse HLA haplotypes.Keywords
This publication has 31 references indexed in Scilit:
- Machine learning competition in immunology – Prediction of HLA class I binding peptidesJournal of Immunological Methods, 2011
- Prediction of epitopes using neural network based methodsJournal of Immunological Methods, 2011
- Autoimmunity associated with immunotherapy of cancerBlood, 2011
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerNucleic Acids Research, 2010
- State of the art and challenges in sequence based T-cell epitope predictionImmunome Research, 2010
- Lessons from Applied Ecology: Cancer Control Using an Evolutionary Double BindCancer Research, 2009
- Expression Hierarchy of T Cell Epitopes from Melanoma Differentiation Antigens: Unexpected High Level Presentation of Tyrosinase-HLA-A2 Complexes Revealed by Peptide-Specific, MHC-Restricted, TCR-Like AntibodiesThe Journal of Immunology, 2009
- Antitumor Activity of Immunotoxins with T-Cell Receptor–like Specificity against Human Melanoma XenograftsCancer Research, 2008
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutationThe Lancet, 1995